Novartis AG
ianalumab
Sjögren’s disease
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews ianalumab for Sjögren’s disease around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 14h ago
“FDA granted Breakthrough Therapy designation and priority review to ianalumab for the treatment of Sjögren’s disease, following the first global Phase III trials to demonstrate a statistically significant reduction in disease activity.”